Cardiol Therapeutics' Phase II ARCHER Trial Results to be Presented at the European Society of Cardiology Scientific Meeting on Myocardial & Pericardial Diseases
The ESC M&PD meeting brings together the world's experts working to improve the treatment of myocarditis and pericarditis. Presentation to provide comprehensive findings from the ARCHER trial following the reporting of topline results demonstrating a notable improvement in extracellular volume and a significant reduction in left ventricular mass. The Company will host a webcast conference call on Decembe
Biotechnology, Cannabis, Health, Cannabis Manufacturer
2025-11-05 7:45 AM EST | Cardiol Therapeutics Inc.
Medexus Schedules Second Fiscal Quarter 2026 Conference Call
Ontario and Chicago, Illinois--(Newsfile Corp. - November 4, 2025) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) plans to host a conference call at 8:00 am Eastern Time on Thursday, November 13, 2025 to discuss Medexus's results for its second fiscal quarter ended September 30, 2025. Medexus expects to file its financial statements and MD&A after markets close on November 12, 2025. To participate in the call, please dial the following numbers:
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2025-11-04 5:30 PM EST | Medexus Pharmaceuticals Inc.
Rize Oncology Announces Completion of Private Placement and Resignation of Director
Kelowna, British Columbia--(Newsfile Corp. - November 4, 2025) - Rize Oncology Inc. (OTC: RZONF) (the "Company"), a clinical-stage pharmaceutical company focused on developing innovative oncology therapeutics, is pleased to announce that on October 30, 2025 it completed a non-brokered private placement (the "Private Placement") of units of the Company (the "Units"), raising gross proceeds of C$500,000. The Private Placement consisted of the issuance of 5,000,000 Un
2025-11-04 4:27 PM EST | Rize Oncology Inc.
Hemostemix Closes Private Placement of $461,230
Calgary, Alberta--(Newsfile Corp. - November 4, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company"), the leading autologous (patient's own) stem cell therapy company offering VesCell™ (ACP-01) to no-option individuals suffering from pain related to angina, peripheral arterial disease, chronic limb threatening ischemia, ischemic cardiomyopathy, non-ischemic dilated cardiomyopathy, congestive heart failure, and total body
Biotechnology, Pharmaceuticals, Health
2025-11-04 3:09 PM EST | Hemostemix Inc.
Envoy Medical Announces First Three Patients Enrolled in Final Stage of Acclaim(R) Cochlear Implant Pivotal Clinical Trial
White Bear Lake, Minnesota--(Newsfile Corp. - November 4, 2025) - Envoy Medical, Inc. (NASDAQ: COCH) ("Envoy Medical" or the "Company"), a hearing health company pioneering fully implanted hearing solutions, today announced that the first three patients have been enrolled in the final stage of the Company's pivotal clinical trial of the full implanted Acclaim® cochlear implant. These initial surgeries in this final stage were performed by Dr. Abraham Jacob at the Center for Neurosciences
Biotechnology, Healthcare and Hospitals
2025-11-04 8:00 AM EST | Envoy Medical, Inc.
BioHarvest Sciences to Host Third Quarter Earnings Call on November 13 at 4:30 p.m. Eastern Time
British Columbia and Rehovot, Israel--(Newsfile Corp. - November 4, 2025) - BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a company pioneering its patented Botanical Synthesis technology platform, today announced that it will release financial results for the third quarter ended September 30, 2025 after market close on Thursday, November 13, 2025. Management will host an inve
Biotechnology, Pharmaceuticals, Health
2025-11-04 7:30 AM EST | BioHarvest Sciences Inc.
Wellgistics Health Enters into LOI to Acquire Kare Rx Hub
Tampa, Florida--(Newsfile Corp. - November 4, 2025) - We
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Blockchain
2025-11-04 6:00 AM EST | Wellgistics Health
Defence Therapeutics Demonstrates Strong Preclinical in Vivo Efficacy Results Evaluating Accum-Kadcyla in Breast Cancer Models
Montreal, Quebec--(Newsfile Corp. - November 4, 2025) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a leading biotechnology company specialized in drug delivery technologies, is pleased to announce and to present today at the World ADC Conference in San Diego, USA, highly encouraging results from its latest preclinical in vivo study evaluating Accum®-Kadcyla, a novel version of Genentech/Roche's marketed ADC Kadcyla® (ado-trastuzumab
Biotechnology, Pharmaceuticals, Health
2025-11-04 3:15 AM EST | Defence Therapeutics Inc.
IR-MED Ltd. Announces Launch of First-in-Human Clinical Trial of Its DiaSafe(TM) Device for Diabetic Foot Ulcer (DFU) Assessment
Rosh Pina, Israel--(Newsfile Corp. - November 3, 2025) - IR-MED Ltd. (OTCQB: IRME) (the "Company" or "IR-Med"), a pioneer in artificial intelligence ("AI")-driven, non-invasive infrared spectrographic medical device develop
Technology, Biotechnology, Healthcare and Hospitals, Health
2025-11-03 4:30 PM EST | IR-MED, Inc.
Phio Pharmaceuticals Announces Exercise of Warrants for Approximately $13.4 Million Gross Proceeds
King of Prussia, Pennsylvania--(Newsfile Corp. - November 3, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer, today announced the entry into definitive agreements to exercise certain outstanding warrants to purchase up to an aggregate of 5,663,182 shares of common stock of the Company originally issued in July 2024, December 2024, Januar
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2025-11-03 1:40 PM EST | Phio Pharmaceuticals Corp.
CellCentric to Host Investor Event and Present Dose Optimization Data from Phase 2 Study of Inobrodib for Multiple Myeloma at the American Society of Hematology (ASH) Annual Meeting
- Preliminary results confirm earlier findings that inobrodib in combination with pomalidomide + dexamethasone (InoPd) for multiple myeloma has promising clinical activity and a tolerable safety profile in a heavily pretreated population - - The Company will host a live investor event on December 7, at 8:00 p.m. ET in Orlando following the poster presentation - Cambridge, United Kingdom and Boston, Massachusetts
2025-11-03 9:00 AM EST | CellCentric, Inc
Phio Pharmaceuticals Announces Positive Pathology Results: Final Maximum Dose Cohort for INTASYL PH-762 Skin Cancer Trial
King of Prussia, Pennsylvania--(Newsfile Corp. - November 3, 2025) - Phio Pharmaceuticals Corp. (NASDAQ
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2025-11-03 7:45 AM EST | Phio Pharmaceuticals Corp.
Britannia Life Sciences Inc. Enters into $11.3 Million Share Exchange Agreement with McEwen Inc. and Britannia Mining Solutions Inc.
Toronto, Ontario--(Newsfile Corp. - November 3, 2025) - Britannia Life Sciences Inc. (CSE: BLAB) ("Britannia" or the "Company") is pleased to announce that it has entered into a share exchange agreement (the "Agreement") with McEwen Inc. ("McEwen") and Britannia Mining Solutions Inc. (doing business as Paragon Geochemical Laboratories Inc.) (together, "Paragon"). Pursuant to the terms of the Agreement, McEwen will acquire 648,002 common shares of Paragon from Britannia at a deemed price
Biotechnology, Household / Consumer / Cosmetics, Health, Cannabis Ancillary Service Provider
2025-11-03 7:07 AM EST | Britannia Life Sciences Inc
Theralase(R) Demonstrates Effectiveness of X-Ray-Activated Drug
Toronto, Ontario--(Newsfile Corp. - November 3, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company pioneering light, radiation, sound and drug-activated therapeutics for the treatment of cancer, bacteria and viruses, is pleased to share a scientific poster which demonstrates the effectiveness of X-Ray-activated Rutherrin® for numerous cancer
Technology, Biotechnology, Healthcare and Hospitals, Pharmaceuticals
2025-11-03 7:00 AM EST | Theralase Technologies Inc.
Phio Pharmaceuticals Announces Appointment of Mr. David H. Deming to the Position of Lead Independent Director
King of Prussia, Pennsylvania--(Newsfile Corp. - October 31, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio is pleased to announce that David Deming has been appointed Lead Independent Director of the Board of Directors of Phio Pharmaceuticals. Mr. Deming brings over 30 years of experience in investment bankin
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2025-10-31 10:15 AM EDT | Phio Pharmaceuticals Corp.
PharmaDrug Announces Debt Restructuring
Toronto, Ontario--(Newsfile Corp. - October 31, 2025) - PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research, development and commercialization of natural medicines is pleased to announce that it has agreed to issue $445,686 principal amount of secured convertible debentures to two current holders of the Company's secured convertible debentures that were past their maturity date. Each Debe
Biotechnology, Cannabis, Psychedelics, Cannabis Manufacturer
2025-10-31 8:58 AM EDT | PharmaDrug Inc.
Anne-Kathrin Stoller to Become New CEO at Bachem
Bubendorf, Switzerland--(Newsfile Corp. - October 31, 2025) - Ad hoc announcement pursuant to Art. 53 LR Anne-Kathrin Stoller to become new CEO at Bachem Bachem (SIX: BANB) announced today that its Board of Directors has appointed Anne-Kathrin Stoller, currently Head of Bachem Americas and previously the company's long-standing Chief Marketing Officer (CMO), as its new CEO, effective January 1, 2026. She succeeds Thomas Meier, wh
Biotechnology, Chemical, Healthcare and Hospitals, Pharmaceuticals
2025-10-31 2:23 AM EDT | Bachem Holding AG
Hemostemix's Boots on the Ground in Florida October Update
Calgary, Alberta--(Newsfile Corp. - October 30, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), the leading autologous (patient's own) stem cell therapy company offering VesCell™ (ACP-01) to no-option individuals suffering from pain related to angina, peripheral arterial disease, chronic limb threatening ischemia, ischemic cardiomyopathy, non-ischemic dilated cardiomyopathy, congestive heart failure, and total body ischemia, today announced major progress in Flori
Biotechnology, Pharmaceuticals, Health
2025-10-30 11:29 AM EDT | Hemostemix Inc.
PharmaDrug Signs Definitive Agreement to Acquire Equity Interest in Canurta Inc
Toronto, Ontario--(Newsfile Corp. - October 30, 2025) - PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research, development and commercialization of natural medicines is pleased to announce that it has executed a definitive securities exchange agreement (the "Definitive Agreement") with Canurta Limited Partnership ("Canurta") and each of the limited partners of Canurta, the parent en
Biotechnology, Cannabis, Psychedelics, Cannabis Manufacturer
2025-10-30 9:00 AM EDT | PharmaDrug Inc.
BioHarvest Sciences Announces Strategic CDMO Partnership to Revolutionize Saffron Compound Production with Botanical Synthesis
British Columbia and Rehovot, Israel--(Newsfile Corp. - October 30, 2025) - BioHarvest Sciences Inc. (NASDAQ: BHST) ("BioHarvest" or the "Company"), a biotechnology company pione
Biotechnology, Pharmaceuticals, Health
2025-10-30 7:30 AM EDT | BioHarvest Sciences Inc.